Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:naloxone
gptkb:buprenorphine |
| gptkbp:approvalYear |
2010
|
| gptkbp:ATCCode |
N07BC51
|
| gptkbp:brand |
buprenorphine/naloxone
|
| gptkbp:contraindication |
hypersensitivity to naloxone
hypersensitivity to buprenorphine |
| gptkbp:firstApprovedCountry |
gptkb:United_States
|
| gptkbp:form |
gptkb:film
12 mg/3 mg 2 mg/0.5 mg 4 mg/1 mg 8 mg/2 mg |
| gptkbp:genericAvailable |
yes
|
| gptkbp:indication |
opioid dependence
|
| gptkbp:isSolubleIn |
mouth
|
| gptkbp:legalStatus |
gptkb:Schedule_III
|
| gptkbp:manufacturer |
Indivior
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:prescriptionStatusUS |
prescription only
|
| gptkbp:riskFactor |
gptkb:orthostatic_hypotension
gptkb:serotonin_syndrome dizziness fatigue hepatitis allergic reaction QT prolongation drowsiness respiratory depression liver toxicity drug interactions dependence adrenal insufficiency abuse potential mouth irritation neonatal opioid withdrawal syndrome precipitated withdrawal mouth numbness mouth redness |
| gptkbp:routeOfAdministration |
sublingual
buccal |
| gptkbp:sideEffect |
nausea
constipation headache sweating insomnia |
| gptkbp:storage |
20-25°C (68-77°F)
|
| gptkbp:usedFor |
medication-assisted treatment
|
| gptkbp:bfsParent |
gptkb:Aquestive_Therapeutics
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Suboxone (film formulation)
|